Literature DB >> 10349698

Future options for the management of hepatitis C.

G L Davis1, D R Nelson, G R Reyes.   

Abstract

Current therapy for hepatitis C virus (HCV) infection is believed to be based in part on the ability of interferons to directly inhibit intracellular HCV replication and prevent infection of uninfected hepatocytes, although the exact mechanisms by which this therapy exerts its effect remain unknown. There are several potential avenues open to development of new antiviral treatment strategies for HCV infection. These include extracellular neutralization of virus to prevent new infection, inhibition of viral entry and uncoating, impairment of intracellular replication by either inhibition of host or viral enzymes or by destruction of the viral genome, enhancement of the host immune response to HCV, or control of the hepatic inflammation that results in progressive liver injury. Although the potential of these therapeutic approaches have been demonstrated in vitro or have been used for the treatment of other infections, their use in man, and so their future and potential efficacy, require further investigation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10349698

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  4 in total

1.  Gary L. Davis, MD: a conversation with the editor. Interview by William Clifford Roberts.

Authors:  Gary L Davis
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

2.  Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes.

Authors:  Heidi Barth; Raffaele Cerino; Mirko Arcuri; Marco Hoffmann; Peter Schürmann; Mohammed I Adah; Bettina Gissler; Xiping Zhao; Valeria Ghisetti; Bruna Lavezzo; Hubert E Blum; Fritz von Weizsäcker; Alessandra Vitelli; Elisa Scarselli; Thomas F Baumert
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 3.  New therapies for chronic hepatitis C virus infection.

Authors:  Anouk Dev; Keyur Patel; John G McHutchison
Journal:  Curr Gastroenterol Rep       Date:  2004-02

4.  Hepatitis C.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.